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doi:10.1Objectives: : Although adequate numbers of hematopoietic progenitor cells reside in the human bone marrow,
the extent of endogenous neovascularization after myocardial infarction remains insufficient. The aim of this
study was to identify the role of the CXC chemokine receptor 4/stromal cell–derived factor 1 axis in the mobi-
lization and homing of hematopoietic progenitor cells in the ischemic heart.
Methods:Human bonemarrow–derived hematopoietic progenitor cells or salinewere injected systemically into
athymic nude rats 48 hours after myocardial infarction.Myocardial and bonemarrow expression of stromal cell–
derived factor 1 and chemotaxis of hematopoietic progenitor cells were measured in vitro in the presence or ab-
sence of stromal cell–derived factor 1. The role of the CXC chemokine receptor 4/stromal cell–derived factor 1
axis was investigated by means of antibody blockade or systemic administration of granulocyte colony-
stimulating factor. Morphologic analysis included measurement of the infarct area, capillary density, and apo-
ptosis, whereas left ventricular function was measured by means of echocardiographic analysis.
Results: Expression of postinfarct stromal cell–derived factor 1 was increased by 67% in the bone marrow and
decreased by 43% in myocardium. Disruption of bone marrow stromal cell–derived factor 1/CXC chemokine
receptor 4 interactions by antibody blockade resulted in a redirection of human hematopoietic progenitor cells
from the bone marrow to the ischemic heart and augmented neovascularization and cardiomyocyte survival.
Similarly, systemic administration of granulocyte colony-stimulating factor to block CXC chemokine receptor
4/stromal cell–derived factor 1 interaction resulted in increased mobilization and homing of hematopoietic pro-
genitor cells to the ischemic heart, which translated to augmented myocardial neovascularization, prevention of
apoptosis, and improved cardiac function.
Conclusions: Bone marrow stromal cell–derived factor 1 upregulation after myocardial ischemia prevents
mobilization of endogenous hematopoietic progenitor cells. We provide evidence that disruption of stromal
cell–derived factor 1/CXC chemokine receptor 4 interactions allows redirection of hematopoietic progenitor
cells to ischemic myocardium and enhances recovery of left ventricular function. (J Thorac Cardiovasc Surg
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SAlthough development of neovascularization is an integral
component of the remodeling process after myocardial in-
farction (MI),1 it is insufficient to keep pace with the tissue
growth required for contractile compensation and is unable
to support the greater demands of the hypertrophied but vi-
able myocardium. Transplantation of ex vivo isolated hema-
topoietic progenitor cells (HPCs) after acute ischemia
results inmyocardial neovascularization, enhancedmyocar-
dial perfusion, and improved functional recovery in both an-
imal models and human subjects.2-5 A combination of
mechanisms enabling egress or migration of HPCs from
the bone marrow to the heart and transplantation of HPCs
in the myocardium might improve the results of cardiac
neovascularization after MI.
Homing and retention of HPCs in mammalian bone
marrow are controlled by interactions between stromalrdiovascular Surgery c Volume 142, Number 3 687
Abbreviations and Acronyms
CXCR4 ¼ CXC chemokine receptor 4
G-CSF ¼ granulocyte colony-stimulating factor
HPC ¼ hematopoietic progenitor cell
IL-8 ¼ interleukin 8
LAD ¼ left anterior descending coronary
artery
mAb ¼ monoclonal antibody
MHC ¼ major histocompatibility complex
MI ¼ myocardial infarction
PCR ¼ polymerase chain reaction
RT–
PCR
¼ reverse transcriptase–polymerase
chain reaction
SCF ¼ stem cell factor
SDF-1 ¼ stromal cell–derived factor 1
VEGF ¼ vascular endothelial growth factor
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Scells and hematopoietic progenitors.6,7 The CXC
chemokine stromal cell–derived factor 1 (SDF-1), which
is constitutively produced by bone marrow stromal cells,
appears to be essential for homing and engraftment of
HPCs.8,9 Systemic treatment with granulocyte colony-
stimulating factor (G-CSF) results in transient egress of
HPCs from the bone marrow into the peripheral circula-
tion.10,11 This phenomenon, termed bone marrow
mobilization, is due to G-CSF–mediated induction and
activation of neutrophil precursors in the bone marrow
and their subsequent secretion of neutrophil proteases,
which directly cleave the N-terminal regions of SDF-1
and CXC chemokine receptor 4 (CXCR4),12,13 as well
as the N-terminal regions of vascular cell adhesion
molecule 1.14
We have previously shown that manipulating CCR3- and
CXCR4-dependent interactions increases migration of hu-
man CD34þprogenitors to myocardial tissue. In the present
study we tested whether in vivo disruption of CXCR4/SDF-
1 interactions could redirect migration of human bone
marrow–derived HPCs to ischemic myocardial tissue and
whether this intervention has any influence on cardiac
recovery.MATERIALS AND METHODS
Purification and Characterization of G-CSF–
Mobilized Human CD34þCells
Cell isolation, purification, and characterization have been described
elsewhere.15 Briefly, single-donor leukapheresis products were obtained
from human subjects treated with recombinant G-CSF (10 mg/kg; Amgen,
Thousand Oaks, Calif) administered subcutaneously daily for 4 days.
Mononuclear cells were separated by using Ficoll-Hypaque, and highly pu-
rified CD34þcells (>98% positive) were obtained by using magnetic beads
coated with anti-CD34 monoclonal antibody (mAb; Miltenyi Biotech,
Auburn, Calif).688 The Journal of Thoracic and Cardiovascular SurgChemotaxis of Human Bone Marrow–Derived HPCs
Highly purified CD34þCD117bright cells were plated in 48-well chemo-
taxis chambers fitted with membranes (8-mm pores; Neuro Probe, Gai-
thersburg, Md). After incubation for 2 hours at 37C, cells were
cultured for 3 hours in medium containing SDF-1 a/b, vascular endothe-
lial growth factor (VEGF), and stem cell factor (SCF), all at a concentra-
tion of 1.0 mg/mL. Chemotaxis was calculated by counting migrating
cells in 10 high-power fields.Myocardial Infarction and Cell Injections
Rowett (rnu/rnu) athymic nude rats (Harlan Sprague–Dawley, Indianap-
olis, Ind) were used in studies approved by the Columbia University Insti-
tute forAnimalCare andUseCommittee. Permanent surgical ligation of the
left anterior descending coronary artery (LAD) and injection of human cells
have been described previously.15 For studies on cellular migration, saline
or 2.03 106 DiI-labeled CD34þcells obtained from a single donor after G-
CSF mobilization were injected into the tail vein 48 hours after LAD liga-
tion in the presence or absence of mAbs against human CXCR4 and CD34
(ImmunoLaboratories, Takasaki, Japan) and rat SDF-1 (R&D Systems,
Minneapolis, Minn) or isotype controls (n ¼ 6–10). Quantitation of cell
homingwas performed bymeans of assessment of DiI fluorescence inmyo-
cardium and flow cytometric and reverse transcriptase–polymerase chain
reaction (RT–PCR) analysis of HLA class I–positive cells in the bone mar-
row. The results were confirmed by means of immunohistochemistry stain-
ing against the human mitochondrial epitope S-100 (S1-61; Santa Cruz
Biotechnology, Santa Cruz, Calif), which is not expressed in rat tissues.Disruption of Bone Marrow CXCR4/SDF-1
Interactions
To investigate the effect of the CXCR4/SDF-1 pathway on retention of
HPCs in the bone marrow and on homing to the myocardium, antibody
blockade of human CXCR4 or rat SDF-1 or systemic administration of
G-CSF was used (Figure E1).Measurement of Rat Myocardial and Bone Marrow
SDF-1 mRNA Expression
RT–PCRwas used to quantify myocardial expression of rat SDF-1 mRNA
at baseline and at 6, 12, 24, and 48hours afterMI byusing the following primer
sequences: rat SDF-1 a, 50-CTGTTGTGCTTACTTGTTTAAGGCTTTGTC-
30 (forward primer) and 50-GACGCCAAGGTCGTCGGT-30 (reverse primer);
rat ribosomal protein L32 (PLR32), 50-CCCTTCGGCCTCTGGTGAAGC-30
(forward primer) and 50-GAACACAAAAACAGGCACACAAGCCATC-30
(reverse primer). Polymerase chain reaction (PCR) was performed with the
GeneAmp PCR System 9700 (Applied Biosystems, Foster City, Calif). PCR
products were analyzed on agarose gel stained with ethidium bromide. RT–
PCR products were quantified by using UN-SCAN-IT software from Silk
Scientific, Inc (Orem, Utah). Values of SDF-1 expression were calculated rel-
ative to the values of PLR32 expression. Datawere expressed as themeans ob-
tained from 3 independent rats for each time point.Measurement of Infarct Size and Capillary Density
and Quantification of Apoptosis
Masson trichrome stain was used to quantify the size of the MI, as de-
scribed previously.15 Quantification of capillary density was performed by
means of antibody staining against rat or humanCD31 (Serotec, Kidlington,
United Kingdom, and Research Diagnostics, Flanders, NJ, respectively),
factor VIII (Dako, Carpinteria, Calif), and rat or humanmajor histocompat-
ibility complex (MHC) class I (Accurate Chemicals, Westbury, NY), as de-
scribed previously.15 For in situ detection of apoptosis at the single-cell
level, we used the TUNELmethod of DNA end-labelingmediated by deox-
ynucleotidyl transferase (Roche Diagnostics, Mannheim, Germany), asery c September 2011
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weeks after MI by a pathologist blinded to the study group.
Echocardiographic Analysis of Myocardial Function
Transthoracic echocardiographic analysiswas performed by using a high-
frequency liner array transducer (SONOS 5500; Hewlett Packard, Andover,
Mass). Two-dimensional images were obtained at the midpapillary and api-
cal levels. End-diastolic (EDV) and end-systolic (ESV) left ventricular vol-
umes were obtained by using the biplane area–length method, and
percentage of left ventricular ejection fraction was calculated as follows:
[(EDVESV)/EDV]3 100.
Statistical Analysis
Statistical analysis was performed with SPSS 17 software (SPSS, Inc,
Chicago, Ill). Continuous variables are presented as means  standard de-
viations. Group means were compared by using the Student’s test and 1-
way analysis of variance with the post-hoc Bonferroni correction. For fur-
ther information regarding the study methodology, see the online-only
‘‘Materials and Methods.’’
RESULTS
Myocardial and Bone Marrow SDF-1 Expression
After Acute MI
Although the ratio of SDF-1 mRNA expression relative
to that of a constitutively expressed control genewas similar
in the myocardium and bone marrow of normal rats, by 12
hours after MI, this ratio decreased by a mean of 43% in
cardiac tissue and increased by a mean of 67% in the
bone marrow, representing a 2.3-fold net increase in the
bone marrow/cardiac SDF-1 mRNA expression ratio
(P<.01). These changes persisted for at least 48 hours after
LAD ligation (Figure 1).
SDF-1 Induces In Vitro Chemotaxis of Bone Marrow
HPCs
After mobilization by G-CSF, CD34þCD117bright cells
constitutively expressed the SDF-1 CXCR4, as well as the
VEGF-binding receptor Flk-1 (Figure 1, B). To examine
whether SDF-1 was a chemoattractant for CD34þCD117bright
cells, positively selected CD34þcells were cultured in RPMI
medium for 12 hours before in vitro chemotactic assays to re-
acquire CXCR4 epitopes that were lost after G-CSF treat-
ment and were necessary for conferring SDF-1 affinity.
Although SDF-1 induced significant in vitro chemotaxis of
CD34þCD117bright cells, neither VEGF nor SCF induced
greater chemotaxis than medium alone (Figure 1, C). The
concentrations of both VEGF and SCF used were sufficient
to induce a more than 2-fold increase in proliferation of
HPCs in culture for 96 hours.
Post-MI SDF-1 Expression in the Bone Marrow
Results in Increased Retention of HPCs
CD34þCD117bright human HPCs were cultured in RPMI
medium for 12 hours before in vivo use to reacquire
CXCR4 epitopes lost after G-CSF treatment (data not
shown). Two days after intravenous injection of culturedThe Journal of Thoracic and Cacells, bone marrow from LAD-ligated rats contained 5-fold
higher levels of human CD34þCD117bright cells compared
with bone marrow from control subjects 2 days after intrave-
nous injection of cultured cells (P<.01; Figure 2, A). Coad-
ministration of mAbs against either human CXCR4 or rat
SDF-1 significantly reduced migration of intravenously
administered human HPCs to ischemic rat bone marrow
compared with anti-CD34 control antibody (both P< .01;
Figure 2, B). Together, these results indicate that the in-
creased expression of SDF-1 in bone marrow of ischemic
rats directly augments HPC retention at this site. Compara-
tive studies on detection ofDiI andMHC class I positive cells
revealed no difference between the 2 detection methods
(Table E1).
Disruption of Bone Marrow CXCR4/SDF-1
Interactions Redirects Human HPCs From the Bone
Marrow to the Ischemic Heart
Next we investigated whether disrupting CXCR4/SDF-1
interactions could reduce HPC retention in the bone marrow
and increase homing to the myocardium in rats with acute
MI. Myocardial trafficking of human HPCs increased by
24% and 17%, respectively, after coadministration of
mAbs against either human CXCR4 or rat SDF-1, respec-
tively (both P<.01; Figure 2, C).
Disruption of Bone Marrow CXCR4/SDF-1
Interactions Augments Cardiac Neovascularization
After Acute Ischemia
Two days after LAD ligation, animals received 2 3 106
human HPCs reconstituted with varying proportions of
CD34þCD117bright angioblasts (103, 105, and 105 plus
anti-CXCR4 mAb). The group receiving 105 HPCs plus
anti-CXCR4 mAb demonstrated greater numbers of capil-
laries compared with the other 2 groups (16.4  1.86 vs
10.25  1.43 and 11.19  1.01, respectively; P< .01;
Figure 3, A). Induction of neovascularization was accompa-
nied by a significant increase in the cellularity of granula-
tion tissue and minimal matrix deposition and fibrosis
(Figure 3, B).
Disruption of Bone Marrow CXCR4/SDF-1
Interactions Augments Cardiomyocyte Survival and
Functional Recovery After Acute Ischemia
Rats receiving 105 HPCs plus anti-CXCR4 mAb demon-
strated a significant reduction in the number of apoptotic
myocytes at the peri-infarct region compared with that
seen in the groups receiving either 103 or 105 HPCs alone
(both P< .001), but in the groups receiving 103 or 105
HPCs, abundant numbers of apoptotic cells in the peri-
infarct region were observed (Figure 4, A). On the contrary,
no improvement in these parameters was observed in the
groups receiving 103 or 105 HPCs in comparison with those
seen in rats receiving saline alone. Animals receiving 105rdiovascular Surgery c Volume 142, Number 3 689
FIGURE 1. Stromal cell–derived factor 1 (SDF-1) expression is increased in bone marrow after acute myocardial ischemia and induces chemotaxis of
hematopoietic progenitor cells. A, Time-dependent changes in SDF-1 mRNA expression relative to that of a constitutively expressed control gene in rat
myocardium and bone marrow after myocardial infarction (MI; means standard errors of the mean). B, Four-parameter flow cytometric phenotypic char-
acterization of granulocyte colony-stimulating factor–mobilized bone marrow–derived cells obtained by means of leukapheresis from a representative adult
human donor. Only live cells were analyzed, as defined by 7-aminoactinomycin D staining (vitality>90%). For each marker used, open areas represent
background log fluorescence relative to isotype control antibody. The angioblast fraction has previously been characterized to reside in the minor
CD34þ population expressing CD117 brightly. The CD34þCD117bright angioblast subset expresses CXC chemokine receptor 4 (CXCR4) but not flk. The
injected CD34þ cells had a purity of greater than 98%. Ninety percent to 95% coexpressed the hematopoietic lineage marker CD45, 60% to 80% coex-
pressed the stem cell factor receptor CD117, and less than 1% coexpressed the monocyte/macrophage lineage marker CD14. C, In vitro chemotaxis of
human hematopoietic progenitor cells (mean  standard error of the mean). VEGF, Vascular endothelial growth factor; SCF, stem cell factor.
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improvement in left ventricular ejection fraction (22% 
2%, P<.001; Figure 4, B) and a reduction left ventricular
end-systolic diameter (24%  4% , P<.001; Figure 4, C;
see also Table E2).
Systemic Administration of G-CSF to Disrupt Bone
Marrow CXCR4/SDF-1 Interactions Results in
Mobilization and Homing of HPCs to Ischemic
Myocardium
To investigate whether disruption of bone marrow
CXCR4/SDF-1 interactions provides a general paradigm
for improving cardiac outcome after acute infarction,
LAD-ligated rats were treated systemically with G-CSF.
G-CSF administration induced a 2- to 3-fold increase in cir-690 The Journal of Thoracic and Cardiovascular Surgculating neutrophil and monocyte/macrophage lineage cell
numbers, indicating successful mobilization. Histologic ex-
amination of heart tissue from ischemic rats treated with G-
CSF at 10 mg/kg for 4 days starting 48 hours after LAD li-
gation revealed a high infiltration grade of polymorphonu-
clear leukocytes and cells of the macrophage lineage in
the peri-infarct region. In addition, numerous CD117þ
mononuclear cells were detected in the peri-infarct regions
of animals treated with G-CSF (Figure 5, A). This indicated
myocardial homing of HPCs after G-CSF mobilization. G-
CSF administration resulted in a 3.5-fold increase in total
blood vessel count in the peri-infarct region (13.85  1.79
vs 3.96  0.69, P<.01; Figure 5, B), in a 36%  16% re-
duction in cardiomyocyte apoptosis at the peri-infarct re-
gion (P<.01; Figure 5, C), and in an improvement in leftery c September 2011
FIGURE 2. Induced expression of stromal cell–derived factor 1 (SDF-1) increases bonemarrow retention of hematopoietic progenitor cells, and disrupting
CXC chemokine receptor 4 (CXCR4)/SDF-1 interactions redirects them to ischemic myocardium. A, Detection of human cells in rat bone marrow 2 days
after intravenous injection. LAD, Left anterior descending coronary artery. B, Bone marrow retention of hematopoietic progenitor cells after coadministra-
tion of monoclonal antibodies against CXCR4 or SDF-1 (mean  standard error of the mean). C, Coadministration of anti-CXCR4 or anti–SDF-1 mono-
clonal antibody significantly increased migration of hematopoietic progenitors to ischemic myocardium, whereas anti-CD34 monoclonal antibody had no
effect (mean  standard error of the mean).
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Sventricular ejection fraction (Figure 5, D), all compared
with corresponding measurements in rats treated with
saline.
DISCUSSION
Binding of the CXC chemokine SDF-1 to its ligand,
CXCR4, is essential for homing and retention of HPCs
in mammalian bone marrow.9,10 Our results indicate that
the increase in bone marrow SDF-1 expression observed
after MI serves to prevent mobilization of HPCs,
which could otherwise induce neovascularization of the
myocardium and improve outcome.3-5 Disrupting bone
marrow CXCR4/SDF-1 interactions resulted in enhanced
myocardial neovascularization, decreased apoptosis
levels, and improved myocardial function.
Cellular activation, chemotaxis, and bone marrow reten-
tion are mediated by the N-terminus of SDF-1, which binds
to CXCR4.17 These activities are lost on exposure to dipep-
tidyl peptidase IV (CD26),18 neutrophil cathepsin G,19 and
elastase,20 as well as tissue metalloproteinases, including
matrix metalloproteinases 2 and 9,21 all of which cleave
the N-terminal residues to generate a truncated and non-
functional chemokine.22 SDF-1–mediated redirection ofThe Journal of Thoracic and Castem cell migration is based on a low to high SDF-1 gradi-
ent. Given the fact that HPCs can secrete high concentra-
tions of SDF-1, one could argue that the beneficial effects
of bone marrow stem cell–based therapy could be associ-
ated with a change in the SDF-1 gradient.23 Moreover,
cell therapy was found to increase the number of stem cells
in the remodeled myocardium and significantly improved
cardiac function.24 The finding of a concomitant increase
in CD34þ, CD117þ, and STRO-1þ cells in the myocardium,
resulting in more capillary density, improved cardiac func-
tion, and a decrease in infarct size, is consistent with our re-
sults.25 The decrease in myocardial SDF-1 production after
the first peak can theoretically be explained by increased
and sustained myocardial apoptosis, which affects cell-
secreting function.
The rationale of SDF-1 pretreatment of the ischemic area
is based on the indispensable improvement of the myocar-
dial matrix to augment the potential of cardiac regenera-
tion.26 In our hands intramyocardial injections of SDF-1
in cases of acute myocardial ischemia induced a 2-fold
greater myocardial neovascularization. Accompanying in-
travenous angioblast injection induced 76% further reduc-
tion in cardiomyocyte apoptosis and resulted in a 3-foldrdiovascular Surgery c Volume 142, Number 3 691
FIGURE 3. Disruption of CXC chemokine receptor 4 (CXCR4)/stromal
cell–derived factor 1 interactions after acute myocardial ischemia redirects
migration of human hematopoietic progenitors to the ischemic heart and
induces neovascularization.A, Relationship between the number of human
hematopoietic progenitors injected intravenously (103, 105, and 105 plus
anti-CXCR4monoclonal antibody) and development of rat peri-infarct neo-
vascularization at 2 weeks defined as the mean number of capillaries/high-
power field. Results are expressed as the mean standard error of the mean
of at least 15 high-power fields (n ¼ 3). B, Myocardial infarct bed 2 weeks
after left anterior descending coronary artery ligation from representative
animals in each group stainedwithMasson’s trichrome (upper panel) or im-
munoperoxidase after binding of CD31monoclonal antibody (lower panel).
The infarct zones of rats receiving either 103 or 105 angioblasts show myo-
cardial scars composed of paucicellular, dense fibrous tissue stained blue by
trichrome (3400). In contrast, the infarct zones of rats injected with 105
hematopoietic progenitors plus anti-CXCR4mAb show significant increase
in cellularity of granulation tissue, minimal matrix deposition and fibrosis,
and numerous medium-sized capillaries of human origin.
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compared with injections of HPCs alone.15 Other authors
have used a local delivery approach either by means of di-
rect injection of SDF-1 in the ischemic area27,28 or by
implanting an SDF-1–seeded patch for controlled SDF-1 re-
lease in the neighboring myocardium.29 Both techniques
led to less cell death and increased homing of transplanted
cell angiogenesis within the hypoxic tissue, ultimately lead-
ing to reduced scarring and improved cardiac function. Ex-
planations of the observed effects of SDF-1 include
increased phosphorylation of Akt and upregulation of
VEGF in response to SDF-1. Other authors used injections
of transfected cells with ex vivo delivered SDF-1 to prove
the same concept. Likewise, SDF-1–expressing cell trans-
plantation augmented stem and progenitor cell migration
to the heart, activated cell survival signaling, and enhanced
angiomyogenesis.30,31
Although an SDF-1 gradient to enable homing of mobi-
lized HPCs is a crucial step in myocardial regeneration,
this is not sufficient in the absence of myocardial injury.32
Our ability to redirect migration of human bone marrow–
derived CD117bright cells to ischemic myocardium through
disruption of CXCR4/SDF-1 interactions after either
administration of G-CSF or specific mAbs provides further
evidence that bone marrow SDF-1 is a biologically active
chemotactic factor for this cell lineage.16
Consistent with our results is the observation that subcu-
taneous injections of G-CSF in patients with acute MI led to
increased mobilization of HPCs into the ischemic myocar-
dium.33 However, the functional activity of the endothelial
progenitor cells, as assessed based on the migratory re-
sponse to VEGF and SDF-1, as well as the surface expres-
sion of the functionally active CXCR4 receptor 6H8, were
significantly reduced after G-CSF treatment. Because cells
mobilized by G-CSF lose N-terminal residues on CXCR4
molecules, which are absolutely necessary for SDF-
mediated chemotaxis,13 and because we observed reduced
SDF-1 expression in the ischemic heart relative to that
seen in nonischemic control hearts, it is likely that homing
of G-CSF–mobilized HPCs to the ischemic heart was due to
local production of chemotactic factors other than SDF-1.
In this regard we have recently shown that myocardial ex-
pression of the interleukin 8 (IL-8)/Gro chemokine family
is significantly induced after acute ischemia and that inter-
actions between IL-8/Gro and CXCR1/2 on G-CSF–mobi-
lized HPCs play a major role in their homing to the
ischemic heart.34 These results are supported by recent clin-
ical trials using G-CSF for treatment of patients with acute
MI; demonstrating no effect of G-CSF on functional im-
provement might support this assumption.35 Whether this
G-CSF mobilization–induced impairment of functional ca-
pacities of HPCs indeed leads to an attenuation of improve-
ment in cardiac function in patients after cell therapy
remains to be elucidated. The use of other mobilizingery c September 2011
FIGURE 4. Disruption of CXC chemokine receptor 4 (CXCR4)/stromal cell–derived factor 1 (SDF-1) interactions after acute myocardial ischemia pre-
vents cardiomyocyte apoptosis and improves cardiac function. A, Reduction of cardiomyocyte apoptosis at the peri-infarct rim in rats receiving 105 hema-
topoietic progenitors (HPCs) together with anti-CXCR4 monoclonal antibody in comparison with rats receiving 103 or 105 HPCs alone (mean  standard
error of the mean, n ¼ 3, P<.01). B and C, Relationship between the number of hematopoietic progenitors injected intravenously (103, 105, and 105 plus
anti-CXCR4mAb) and improvement in left ventricular ejection fraction at 15 weeks (B) and mean reduction in left ventricular end-systolic area (C; mean
standard error of the mean, both P<.001).
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tory capacity of circulating HPCs, might be a preferred op-
tion for future treatment of ischemic disease.
Although we have found that IL-8/Gro-amRNA and pro-
tein expression increases by more than 8- to 10-fold within
12 hours of acute myocardial ischemia in rats, these levels
return to baseline by 2 weeks. The transient nature of these
myocardial chemotactic signals suggest that strategies to
disrupt CXCR4/SDF-1 interactions might not, by them-
selves, be effective for myocardial homing of bone marrow
HPCs at times more remote from the acute ischemic event.
CXCR4/SDF-1 interactions in the ischemic myocardium
appear to be complicated because this axis is influenced
by production of a variety of chemokines, which change
over time after MI.36 Upregulation of both chemokines in
cases of acute ischemia explains why transplantation of
SDF-1– or CXCR-4–overexpressing mesenchymal cells
could enhance mesenchymal cell therapy.37,38 However,
the upregulation of SDF-1 andCXCR4 is not a simultaneous
process. A multivariate analysis of the Reinfusion of En-
riched Progenitor Cells and Infarct Remodeling in AcuteThe Journal of Thoracic and CaMyocardial Infarction (REPAIR-AMI) trial39 showed that
when magnitude of SDF-1 migration was included as a vari-
able, treatment time after MI was no longer a predictor of
response to therapy. These data suggest that the bone mar-
row alters its responsiveness to SDF-1 over time, indicating
that bone marrow stem cells might be more responsive to
SDF-1 4 to 7 days after MI than at baseline. One strategy
would include a temporal alignment of SDF-1 and cardio-
myocyte CXCR4 expression, whereas a second strategy
would take into consideration secretion of other chemo-
kines. Other growth factors, such as fibroblast growth factor
2, can lead to synergistic upregulation of CXCR4 in the set-
ting of hypoxia.40 An additional improvement of the matrix
milieu has also been suggested because upregulation of ma-
trix metalloproteinases has been found to enhance the abil-
ity of transplanted or mobilized cells to generate new
myocytes.41 Additionally, as described in a previous study,
increased homing of progenitors into the ischemic myocar-
dium might imply the involvement of alternate mecha-
nisms, such as IL-8/Gro-CXCR1/2,16 which have not been
addressed in this study.rdiovascular Surgery c Volume 142, Number 3 693
FIGURE 5. Granulocyte colony-stimulating factor (G-CSF) administration after acute myocardial ischemia induces neovascularization, prevents cardio-
myocyte apoptosis, and improves cardiac function. A, Detection of human hematopoietic progenitor cells (HPCs; arrows) stained positive for humanMHC
class I b2-microglobulin at the peri-infarct region after G-CSF treatment. B, Increase in total blood vessel count at the peri-infarct region 2 weeks after ad-
ministration of human G-CSF (P<.01, mean  standard error of the mean, n ¼ 3). C, Quantitative analysis of cardiomyocyte apoptosis at the peri-infarct
region 2 weeks after treatment (mean standard error of themean,P<.01).Arrows show cells with apoptotic nuclei. D, changes in ejection fraction between
2 days and 2 weeks after myocardial infarction in G-CSF–treated animals and saline-treated control animals (mean  standard error of the mean, P<.01).
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xenogeneic cell transplantation in nude rats. Although the
model used is a widely accepted in investigational studies
of cardiac regeneration, extrapolation of the results in en-
dogenous or autologous cells might be limited.
We provide evidence that bone marrow SDF-1 upregula-
tion after MI is a negative regulatory factor for mobilization
of HPCs and prevents their homing in ischemic myocar-
dium. Because disruption of bone marrow CXCR4–SDF-1
interactions resulted in increased neovascularization, our
results suggest a general paradigm by which myocardial re-
covery can be enhanced after acute ischemia. The use of ad-
ditional cell therapeutic techniques should only be
considered under the prism of concomitant improvement
of the extracellular environment to which the cells are ex-
pected to adhere and proliferate. Myocardial cell-specific
disruption of CXCR4/SDF-1 interactions could prove help-
ful in improvement of the extracellular milieu and enhance
the results of cell transplantation.40
We acknowledge the contribution of Douwe Atsma and Arnoud
van der Laarse from the Department of Cardiology, Leiden Uni-
versity Medical Center, for critical reading and correction of the
manuscript.
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E-MATERIALS AND METHODS
Quantitation of Cellular Migration Into Tissues
After intravenous injection of human cells, quantitative analysis of the
proportion of human cells in rat bone marrow and heart tissue was per-
formed by means assessment of both DiI fluorescence and expression of
MHC class I proteins. A single-cell suspension of rat bone marrow was
stained with fluorescein-conjugated mAbs against human CD34 and
MHC class I b2-microglobulin (Accurate Chemicals, New Haven, Conn)
and analyzed by means of multiparameter fluorescence with FACScan
(Becton Dickinson, Mountain View, Calif), as described previously.E1
The proportion of human cells in rat heart tissue was expressed as the num-
ber of DiI-positive cells per high-power field (minimum of 5 fields
examined per sample) and as the proportion of cells staining positive for
human MHC class I b2-microglobulin. Staining of cardiac tissue was per-
formed by using an immunoperoxidase technique with an Avidin/Biotin
Blocking Kit, a rat-absorbed biotinylated anti-mouse IgG, and a peroxidase
conjugate (all Vector Laboratories, Burlingame, Calif). The human origin
of the detected cells was confirmed by staining against the human-
mitochondrial epitope S-100 (S1-61, Santa Cruz Biotechnology).
FIGURE E1. A–D, Workflow of experiments to investigate CXCR4/SDF-1 interactions after myocardial infarction and transplantation of G-CSF–mobi-
lized hematopoietic progenitors. CXCR4, CXC chemokine receptor 4; SDF-1, stromal cell–derived factor 1; G-CSF, granulocyte colony-stimulating factor;
HPC, hematopoietic progenitor cell.
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TABLE E1. Comparison of DiI-positive and human MHC class I b2–positive cells in rat myocardium
DiI MHC class I P value
Cells in rat bone marrow 2 d after injection (%) 3.6  0.7 3.9  0.8 .27
Inhibition of HPC trafficking to bone marrow (%)
Anti-CXCR4 76.2  2.1 78.9  2.4 .39
anti–SDF-1 64.8  3.6 64.1  4.1 .31
Anti-CD34 3.6  0.5 4  0.4 .27
Increase of HPC trafficking to ischemic myocardium
Anti-CXCR4 22.9  5.3 24.8  6.3 .19
Anti–SDF-1 20.5  6.3 18.1  8.6 .26
Anti-CD34 3.2.6  1.6 3.9  1.4 .24
DiI, 1,10-dioctadecyl-3,3,30,30-tetramethylindocarbocyanine perchlorate; MHC, major histocompatibility complex; HPC, hematopoietic progenitor cell; CXCR4, CXC chemo-
kine receptor 4; SDF-1, stromal cell–derived factor 1.
TABLE E2. Echocardiographic results after systemic injections of hematopoietic progenitors 48 hours after myocardial infarction
Control HPC 103 HPC 105 HPC 105þanti-CXCR4
Baseline
LVEF (%) 37.3 38.5 39.1 36.7
LVESD (cm) 0.46 0.41 0.44 0.47
LVEDD (cm) 0.73 0.67 0.72 0.74
15 wk
LVEF (%) 38.7 47.1 43.5 57.4
LVESD (cm) 0.45 0.40 0.43 0.36
LVEDD (cm) 0.73 0.76 0.76 0.85
HPC, Hematopoietic progenitor cell; CXCR4, CXC chemokine receptor 4; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVEDD, left
ventricular end-diastolic diameter.
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